quinazolines has been researched along with scopolamine hydrobromide in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appenroth, D; Decker, M; Fleck, C; Lehmann, J; Mohr, K; Tränkle, C | 1 |
| Darras, FH; Decker, M; Khan, N; Pockes, S; Sadek, B | 1 |
| Cheng, X; Deng, G; Ding, W; Guan, H; Ju, Z; Li, S; Liu, W; Ma, C; Rong, X; Wang, C; Wang, Y; Wu, C | 1 |
| Dong, YH; Huang, XF; Ke, HM; Song, GQ; Wang, JH; Xu, DF | 1 |
| Amin, KM; George, RF; Hegazy, GH; Ibrahim, NR; Mohamed, NM | 1 |
5 other study(ies) available for quinazolines and scopolamine hydrobromide
| Article | Year |
|---|---|
In vivo investigations on the cholinesterase-inhibiting effects of tricyclic quinazolinimines: scopolamine-induced cognitive impairments in rats are attenuated at low dosage and reinforced at higher dosage.
Topics: Allosteric Regulation; Animals; Azocines; Cholinergic Antagonists; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Drug Interactions; Female; Imines; Maze Learning; Memory, Short-Term; Quinazolines; Rats; Rats, Wistar; Scopolamine; Tritium | 2008 |
The dual-acting AChE inhibitor and H3 receptor antagonist UW-MD-72 reverses amnesia induced by scopolamine or dizocilpine in passive avoidance paradigm in rats.
Topics: Amnesia; Analysis of Variance; Animals; Avoidance Learning; Cholinesterase Inhibitors; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Histamine H3 Antagonists; Male; Pyrroles; Pyrrolidines; Quinazolines; Quinazolinones; Rats; Rats, Wistar; Scopolamine | 2016 |
Ameliorative effect of deoxyvasicine on scopolamine-induced cognitive dysfunction by restoration of cholinergic function in mice.
Topics: Acetylcholine; Alkaloids; Amnesia; Animals; Antioxidants; Brain-Derived Neurotrophic Factor; Cholinesterase Inhibitors; Cognitive Dysfunction; Hippocampus; Male; Memory; Memory Disorders; Mice, Inbred C57BL; Neurotransmitter Agents; Oxidative Stress; Peganum; Quinazolines; Scopolamine; Sesquiterpenes | 2019 |
Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinergic Antagonists; Cognitive Dysfunction; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Indole Alkaloids; Mice; Models, Molecular; Molecular Structure; Morris Water Maze Test; Phosphodiesterase 5 Inhibitors; Protein Conformation; Quinazolines; Scopolamine | 2020 |
Design, synthesis, and pharmacological characterization of some 2-substituted-3-phenyl-quinazolin-4(3H)-one derivatives as phosphodiesterase inhibitors.
Topics: Animals; Behavior, Animal; Blood-Brain Barrier; Cognitive Dysfunction; Disease Models, Animal; Inhibitory Concentration 50; Mice; Molecular Docking Simulation; Phosphodiesterase Inhibitors; Quinazolines; Scopolamine; Structure-Activity Relationship; Sulfides | 2021 |